These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

693 related items for PubMed ID: 29377877

  • 41. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 42. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis.
    Boudreault AA, Xie H, Rakita RM, Scott JD, Davis CL, Boeckh M, Limaye AP.
    Transpl Infect Dis; 2011 Jun 15; 13(3):244-9. PubMed ID: 21414119
    [Abstract] [Full Text] [Related]

  • 43. Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab.
    Andrade-Sierra J, Heredia-Pimentel A, Rojas-Campos E, Ramírez Flores D, Cerrillos-Gutierrez JI, Miranda-Díaz AG, Evangelista-Carrillo LA, Martínez-Martínez P, Jalomo-Martínez B, Gonzalez-Espinoza E, Gómez-Navarro B, Medina-Pérez M, Nieves-Hernández JJ.
    Int J Infect Dis; 2021 Jun 15; 107():18-24. PubMed ID: 33862205
    [Abstract] [Full Text] [Related]

  • 44. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
    Bordon V, Bravo S, Van Renterghem L, de Moerloose B, Benoit Y, Laureys G, Dhooge C.
    Transpl Infect Dis; 2008 Feb 15; 10(1):19-23. PubMed ID: 17511814
    [Abstract] [Full Text] [Related]

  • 45. Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney-transplant patients.
    Kamar N, Mengelle C, Esposito L, Guitard J, Mehrenberger M, Lavayssière L, Ribes D, Cointault O, Durand D, Izopet J, Rostaing L.
    J Med Virol; 2008 Jun 15; 80(6):1012-7. PubMed ID: 18428146
    [Abstract] [Full Text] [Related]

  • 46. Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss.
    Andrei G, Van Loon E, Lerut E, Victoor J, Meijers B, Bammens B, Sprangers B, Gillemot S, Fiten P, Opdenakker G, Lagrou K, Kuypers D, Snoeck R, Naesens M.
    Antiviral Res; 2019 Aug 15; 168():203-209. PubMed ID: 31212020
    [Abstract] [Full Text] [Related]

  • 47. Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression.
    Shah AP, Chen JM, Fridell JA.
    Clin Transplant; 2015 Dec 15; 29(12):1221-9. PubMed ID: 26458498
    [Abstract] [Full Text] [Related]

  • 48. Evaluating Real-World Experience With Maribavir for Treatment of Refractory/Resistant Cytomegalovirus in Renal Transplant Recipients.
    Beechar VB, Phadke VK, Pouch SM, Mehta AK, Karadkhele G, Larsen CP, Woodworth MH.
    Clin Transplant; 2024 Oct 15; 38(10):e15480. PubMed ID: 39427300
    [Abstract] [Full Text] [Related]

  • 49. Impact of an ultrasensitive Cytomegalovirus quantitative nucleic acid test on Cytomegalovirus detection and therapy in renal transplant recipients.
    Beechar VB, Pouch SM, Phadke VK, Karadkhele G, Larsen CP, Woodworth MH.
    Transpl Infect Dis; 2024 Feb 15; 26(1):e14219. PubMed ID: 38158932
    [Abstract] [Full Text] [Related]

  • 50. Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction.
    Couzi L, Helou S, Bachelet T, Martin S, Moreau K, Morel D, Lafon ME, Garrigue I, Merville P.
    Transplant Proc; 2012 Nov 15; 44(9):2809-13. PubMed ID: 23146529
    [Abstract] [Full Text] [Related]

  • 51. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T, Nampoory MR, Johny KV, Pacsa AS, Mini Abraham P, Nair MP, Abdel-Haleem M, Samhan M, Al-Mousawi M.
    Transplant Proc; 2004 Nov 15; 36(6):1847-9. PubMed ID: 15350495
    [Abstract] [Full Text] [Related]

  • 52. Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.
    Fallatah SM, Marquez MA, Bazerbachi F, Schiff JR, Cattral MS, McGilvray ID, Norgate A, Selzner M, Rotstein C, Husain S.
    Clin Transplant; 2013 Nov 15; 27(4):503-9. PubMed ID: 23731387
    [Abstract] [Full Text] [Related]

  • 53. Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience.
    Jongsma H, Bouts AH, Cornelissen EA, Beersma MF, Cransberg K.
    Pediatr Transplant; 2013 Sep 15; 17(6):510-7. PubMed ID: 23890076
    [Abstract] [Full Text] [Related]

  • 54. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ, Malaise J, Moreno A, Crespo M, Fernández-Cruz L, Euro-SPK Study Group.
    Nephrol Dial Transplant; 2005 May 15; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [Abstract] [Full Text] [Related]

  • 55. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
    Cristelli MP, Esmeraldo RM, Pinto CM, Sandes-Freitas TV, Felipe C, Lobo CF, Viana L, Mansur J, Stopa S, Santos DWC, Grenzi PC, Aguiar WF, Tedesco-Silva H, Pestana JOM.
    Transpl Infect Dis; 2018 Aug 15; 20(4):e12907. PubMed ID: 29679515
    [Abstract] [Full Text] [Related]

  • 56. A risk-stratified approach to cytomegalovirus prevention in pediatric solid organ transplant recipients.
    Suresh S, Lee BE, Robinson JL, Akinwumi MS, Preiksaitis JK.
    Pediatr Transplant; 2016 Nov 15; 20(7):970-980. PubMed ID: 27565955
    [Abstract] [Full Text] [Related]

  • 57. Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: A retrospective study.
    Herrera S, Khan B, Singer LG, Binnie M, Chaparro C, Chow CW, Martinu T, Tomlinson G, Keshavjee S, Husain S, Tikkanen JM.
    Transpl Infect Dis; 2020 Aug 15; 22(4):e13277. PubMed ID: 32170813
    [Abstract] [Full Text] [Related]

  • 58. Selection of More Vulnerable Patients for Cytomegalovirus Infection in Renal Transplant Recipients With Antithymocyte Globulin Induction Therapy: An Analysis of Risk Factors and Cell-Mediated Immunity.
    Jun KW, Lim JH, Hwang JK, Park SC, Kim JI, Yun SS, Kim MH.
    Transplant Proc; 2021 Sep 15; 53(7):2252-2260. PubMed ID: 34452738
    [Abstract] [Full Text] [Related]

  • 59. Risk Factors of Cytomegalovirus Disease in Kidney Transplant Recipients: A Single-Center Study in Thailand.
    Chiasakul T, Townamchai N, Jutivorakool K, Chancharoenthana W, Thongprayoon C, Watanatorn S, Avihingsanon Y, Praditpornsilpa K, Srisawat N.
    Transplant Proc; 2015 Oct 15; 47(8):2460-4. PubMed ID: 26518951
    [Abstract] [Full Text] [Related]

  • 60. Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status.
    Servais S, Dumontier N, Biard L, Schnepf N, Resche-Rigon M, Peffault de Latour R, Scieux C, Robin M, Meunier M, Xhaard A, Sicre de Fontbrune F, Le Goff J, Socié G, Simon F, Mazeron MC.
    Clin Microbiol Infect; 2016 Mar 15; 22(3):289.e1-7. PubMed ID: 26627339
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.